The new EU regulation introduces Joint Clinical Assessments that will run in parallel with EMA approvals, delivering comparative effectiveness data within one month of market authorisation.

A new suit has been filed against IBM claiming that the plan’s target date fund (TDF) series “has suffered over $1.9 billion in losses resulting from the fiduciary breaches at issue and remain ...

Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsJason English - Interim Head of Investor ...

Belimumab is linked to a reduced risk for all-cause mortality compared with azathioprine, methotrexate, and mycophenolate among patients with nonrenal SLE.

Jaala Hinchcliffe’s under siege at DPS, inside the building where politics and public service collide in the most combustible ...

Mind Medicine Australia clinic joins Psyence BioMed’s expanding network of clinical sites as enrollment accelerates in the landmark Phase IIb study for Adjustment Disorder in palliative careNEW YORK, ...

Third quarter sales increased 3.8% to $211.4 million driven by Aerospace growth of 8.5% to $192.7 million. Third quarter net loss was $11.1 million, reflecting $32.6 million in re ...

Psyence Biomedical (PBM) announced a major clinical milestone with multiple patients successfully dosed in its ongoing Phase IIb clinical trial ...

Q2 2026 Earnings Call November 6, 2025 5:00 AM ESTCompany ParticipantsAllison Kirkby - CEO & DirectorSimon Lowth - CFO ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. (OTCQX: VXRT), a clinical-stage ...

The St. Catharines 2026 budget was presented under strong-mayor legislation Wednesday night and it’s now in city council’s ...